Form 4: Marimed CEO Levine Converts RSUs, Adjusts Holdings

Marimed Inc.'s President and CEO, Jon R. Levine, converted Restricted Stock Units into common stock and sold shares to cover tax obligations.

Summary

• Jon R. Levine, President and CEO, Director, and 10% Owner of Marimed Inc., reported transactions on September 15, 2025.
• Levine acquired 89,860 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• Concurrently, 26,374 shares of common stock were disposed of at a price of $0.1374 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Levine directly beneficially owns 20,847,234 shares of common stock.
• Additionally, 6,684,640 shares are indirectly beneficially owned through the Jon Levine Family Trust, though Levine disclaims beneficial ownership for Section 16 purposes.
• The RSUs converted were part of a grant made on May 9, 2025, with remaining RSUs scheduled to vest on December 15, 2025.

Sentiment

Score: 7

Explanation: The filing reflects a routine executive compensation event (RSU vesting) and subsequent tax-related share disposition. It indicates continued executive ownership and alignment, which is generally positive, but does not introduce new strategic or financial news.

Positives

• Conversion of RSUs into common stock indicates a vesting event, often tied to performance or tenure, reflecting a standard component of executive compensation.
• The CEO's continued significant direct and indirect ownership (over 27 million shares combined) demonstrates alignment with shareholder interests.

Negatives

• A portion of shares (26,374) was sold to cover tax obligations, which is a common practice but reduces direct holdings.

Future Outlook

Remaining Restricted Stock Units (RSUs) granted on May 9, 2025, are scheduled to vest on December 15, 2025, indicating a future increase in direct shareholdings for the reporting person, subject to tax withholding.

Management Comments

• The reporting person disclaims beneficial ownership of shares held by the Jon Levine Family Trust for Section 16 purposes.

Industry Context

This filing is a routine insider transaction (Form 4) and does not provide broader industry context. It reflects standard compensation practices involving equity awards for executives.

Comparison to Industry Standards

• The conversion of Restricted Stock Units (RSUs) and subsequent sale of shares for tax withholding is a common practice for executive compensation across various industries. It aligns with typical equity incentive plans designed to align management interests with shareholder value over time. No specific comparable companies or projects are mentioned in this transactional filing.

Related Party Transactions

• Shares held indirectly by the Jon Levine Family Trust are for the benefit of the Reporting Person's spouse and children, which constitutes a related party holding, though beneficial ownership is disclaimed for Section 16 purposes.

Stakeholder Impact

• Shareholders: The CEO's continued significant direct and indirect ownership aligns management interests with shareholder value. The RSU vesting is a standard compensation event.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The remaining Restricted Stock Units (RSUs) granted on May 9, 2025, are scheduled to vest on December 15, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and the sale of shares to cover tax obligations. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The CEO's continued substantial ownership is a positive for alignment, but the transaction itself is neutral in terms of immediate investment implications.

Keywords

Marimed Inc., MRMD, Jon R. Levine, Form 4, Insider Trading, Restricted Stock Units, RSU Conversion, Stock Holdings, CEO, Director, 10% Owner